Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 million With 18% operating income2 growth top end of the 2024 outlook range reached Reported operating income grew by 2%, reported net income3 by +8% Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is ...